Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index; 57 of the 135 sources its claims cite were checked for support.
Abstract
The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset dementia. The diagnosis of bvFTD remains challenging because of the limited accuracy of neuroimaging in the early disease stages and the absence of molecular biomarkers, and therefore relies predominantly on clinical assessment. BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders. To date, ∼50% of patients with bvFTD receive a prior psychiatric diagnosis, and average diagnostic delay is up to 5-6 years from symptom onset. It is also not uncommon for patients with primary psychiatric disorders to be wrongly diagnosed with bvFTD. The Neuropsychiatric International Consortium for Frontotemporal Dementia was recently established to determine the current best clinical practice and set up an international collaboration to share a common dataset for future research. The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment. A systematic literature search with a narrative review was performed to determine all bvFTD-related diagnostic evidence for the following topics: bvFTD history taking, psychiatric assessment, clinical scales, physical and neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural neuroimaging, functional neuroimaging, CSF and genetic testing. For each topic, responsible team members proposed a set of minimal requirements, optimal clinical recommendations, and tools requiring further research or those that should be developed. Recommendations were listed if they reached a ≥ 85% expert consensus based on an online survey among all consortium participants. New recommendations include performing at least one formal social cognition test in the standard neuropsychological battery for bvFTD. We emphasize the importance of 3D-T1 brain MRI with a standardized review protocol including validated visual atrophy rating scales, and to consider volumetric analyses if available. We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD when normal, whereas non-specific regional metabolism abnormalities should not be over-interpreted in the case of a psychiatric differential diagnosis. We highlight the potential role of serum or CSF neurofilament light chain to differentiate bvFTD from primary psychiatric disorders. Finally, based on the increasing literature and clinical experience, the consortium determined that screening for C9orf72 mutation should be performed in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
Overview
CoChat Summary
TL;DR
This consensus review from the Neuropsychiatric International Consortium for Frontotemporal Dementia summarizes evidence and expert recommendations for distinguishing behavioural variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPD). It recommends formal social cognition testing, standardized 3D-T1 MRI review, cautious FDG-PET interpretation, consideration of neurofilament light chain, and C9orf72 screening in possible/probable bvFTD or suspected cases with strong psychiatric features.
Key findings
- bvFTD is frequently misdiagnosed: around 50% of patients receive a prior psychiatric diagnosis, average diagnostic delay is up to 5–6 years from symptom onset, possible bvFTD criteria had poor specificity (27%) in a mixed neuropsychiatric cohort, standard MRI sensitivity was 70%, and FDG-PET specificity was 68% because of frequent non-specific abnormalities in PPD.
- New or emphasized recommendations include at least one formal social cognition test in the standard neuropsychological battery for bvFTD; 3D-T1 brain MRI with a standardized review protocol and validated visual atrophy rating scales, considering volumetric analyses if available; FDG-PET to support exclusion when normal, while non-specific regional hypometabolism should not be over-interpreted in a psychiatric differential diagnosis; consideration of serum or CSF neurofilament light chain (NfL) where reference values are available; and C9orf72 screening in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
- Biomarker evidence cited: CSF NfL discriminated bvFTD from PPD with an AUC of 0.93 in a study of 22 bvFTD and 25 PPD patients; plasma NfL showed AUCs of 0.89–0.94 against schizophrenia, depression, and bipolar disorder, and 0.83 in a larger study of 66 bvFTD and 34 PPD patients; CSF NfL discriminated FTD mutation carriers from controls with an AUC of 0.99.
- Clinical scales and cognitive tests have mixed utility: the Frontal Behavioral Inventory overall score does not distinguish bvFTD from PPD, but a positive FBI subscale score >12 was indicative of bvFTD in late-onset behavioural changes; MMSE was unsuccessful for discrimination; MoCA had 88% classification accuracy for brief cognitive screening but uncertain value against PPD; the Institute of Cognitive Neurology Frontal Screening may have discriminatory power; and a meta-analysis indicated social cognition impairment in bvFTD is more severe than in major psychiatric and developmental disorders.
Methods
- Systematic literature search in Medline (PubMed) and Embase, completed September 2017, retrieving articles from 1992 to 2017, with relevant later references allowed; topics included bvFTD history taking, psychiatric assessment, clinical scales, physical/neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural and functional neuroimaging, CSF, and genetic testing.
- Each topic was assigned to two to three NIC-FTD members based on expertise; teams reviewed abstracts and proposed minimal requirements, clinical recommendations, and tools requiring further research; an in-person meeting was held in Sydney on 13 November 2018, followed by two rounds of draft review and teleconferences.
- Final consensus was obtained through an online survey of all co-authors, with ≥85% approval required to include recommendations.
Limitations
- The paper states that diagnostic methods useful for distinguishing bvFTD from other dementias, such as clinical scales and cognitive tests, do not fare as well against PPD; some patients remain diagnostically ambiguous despite optimal clinical investigation, so longitudinal follow-up often becomes the diagnostic arbiter until pathology is available; non-progressive bvFTD phenocopy cases are particularly challenging, with small sample studies and some showing no FTLD pathological changes.
- The paper states a need for better prognostic tools; CSF biomarkers require study in larger, ideally pathologically and/or genetically confirmed bvFTD cohorts; volumetric and machine-learning MRI methods lack replication and prospective validation at the individual subject level; and many social cognition instruments lack normative data and transcultural adaptation.
- Evident from the text: the recommendations are consensus-based (≥85% expert approval) rather than prospectively validated, and many cited diagnostic accuracy estimates come from small or single studies; the systematic search ended in September 2017, with later references added non-systematically.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Valid · 11 Not valid · 43 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients with FTD secondary to the C9orf72 mutation can present with heterogeneous neuropsychiatric phenotypes (such as lateonset psychosis or mania) without family history, sometimes several years prior to onset of more typical bvFTD features (Ducharme et al. , 2017).”
What the sources say
- Supportedcites Ducharme et al., 2017 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Mild Behavioral Impairment Checklist is a more specific tool to measure later-life behavioural changes that can be the harbinger of dementia (Ismail et al. , 2017); however, it does not facilitate the differentiation of PPD from bvFTD.”
What the sources say
- Supportedcites Ismail et al., 2017 source
The citation is attached to the first clause, which describes the MBI-C as a tool for measuring later-life behavioural changes that may precede dementia. The Discussion says it was created to measure behavioural changes in older adults that might precede dementia. The subsequent statement about differentiating PPD from bvFTD is not attributed to this source by the citation placement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“DAPHNE, a recently developed informant-based behavioural inventory with 10 items based on the 2011 bvFTD international consensus diagnostic criteria, demonstrated an ability to distinguish bvFTD from bipolar disorder (Boutoleau-Bretonniere et al. , 2015).”
What the sources say
- Supportedcites Boutoleau-Bretonniere et al., 2015 source
The Results (Validation of the DAPHNE Scale; page not provided) state that DAPHNE differentiated bvFTD from the comparison groups, including patients with bipolar disorder. The Abstract (Objective) describes a ten-item inventory adapted from Rascovsky’s criteria, and the Methods describe its administration to caregivers. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“On the IFS, however, patients with bvFTD scored significantly worse on several sub-items than subjects with major depression and bipolar disorder (Fiorentino et al. , 2013).”
What the sources say
- Partly supportedcites Fiorentino et al., 2013 sourceExperimental — accuracy not yet measured
The Results report significantly lower bv-FTD scores than depression scores on five IFS subtests. The Methods identify the comparison group as patients with unipolar depression; the cited study does not support the claim about bipolar disorder. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Major consensus dementia investigation guidelines all recommend structural brain imaging as part of the investigation of bvFTD (Knopman et al. , 2001; Filippi et al. , 2012; Soucy et al. , 2013).”
What the sources say
- Not checked — no full text of the sourcecites Knopman et al. , 2001 source
- Supportedcites Filippi et al. , 2012 source
The Background states that European, UK and US guidelines recommend structural imaging when assessing suspected dementia. The paper’s Recommendations for structural MRI call for structural imaging at least once in the diagnostic work-up, and its recommendations identify frontal and temporal atrophy as findings to assess in FTD. (LLM, conf=0.91)
- Partly supportedcites Soucy et al. , 2013 sourceExperimental — accuracy not yet measured
The CCCDTD4 recommendations (Table 1; page unavailable) say structural imaging is indicated for most people with cognitive impairment, but not required for all. The “Structural neuroimaging in memory clinics” section says MRI is preferred for detecting atrophy patterns in fronto-temporal dementias. The paper therefore supports imaging as relevant to investigating these dementias, but does not establish that all major consensus guidelines recommend it specifically for bvFTD. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims · 26 with their cited sources checked
Create a free account to see all 101 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the absence of molecular biomarkers, and when combined with the syndromic overlap with other neurodegenerative disorders and psychiatric disorders, a confirmed behavioral variant frontotemporal dementia (bvFTD) diagnosis is often difficult to achieve and heavily relies on brain imaging. 6”
From MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia (2021) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to its clinical and pathological heterogeneity and symptomatic overlap with other neurodegenerative diseases, such as Alzheimer’s disease (AD), and other non-neurodegenerative psychiatric disorders, the differential diagnosis of FTD remains challenging [2, 7–9].”
From A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the differentiation between FTD and non‐neurodegenerative disorders, several CSF studies showed an excellent performance of NfL for discriminating FTD from psychiatric disorders (AUC > 0.90) 56 , 71 , 75 and consequent perceived added clinical use for the physician.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, serum NfL has the highest diagnostic accuracy with AUC of up to 0.94 for differentiating FTD from primary psychiatric disorders.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The construct of social cognition, including emotion recognition, theory of mind, empathy, and moral reasoning, has been proven difficult to measure in clinical practice. 71”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Self-citationKok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationThe FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
Meeting of minds: the medial frontal cortex and social cognition
Amodio, D. M., & Frith, C. D. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1884 · Cited by 3,782
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Research works printed but not linked: 1
- Cerami, 2014, Optimized objective SPM analysis improves accuracy of [18F]FDG-PET imaging in dementia diagnosis, Eur J Neurol, 21, 303
Cited by
Items 101–200 of 328
Bergh, S., Cheong, R. Y., Petersén, Å., & Gabery, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.984317 · Cited by 11
“This, therefore, poses a diagnostic difficulty in the clinical setting (Ducharme et al., 2020).”
BackgroundKrishnadas, N., Chew, M., Sutherland, A., Christensen, M., Rogers, K., Kyndt, C., Islam, F., Darby, D., & Brodtmann, A. G. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200360 · Cited by 13
Major Depression and Onset of Frontotemporal Dementia
Urban‐Kowalczyk, M., Kasjaniuk, M., Śmigielski, J., & Kotlicka‐Antczak, M. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s390385 · Cited by 8
Piguet, O., Clarke, A. J., Foxe, D., Tse, N. Y., Teng, C., Burrell, J. R., Cheung, S. C., Carrick, J., Devenney, E. M., Halliday, G. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70604 · Cited by 14
“22 Similarly, language and episodic memory deficits, which are characteristic of Alzheimer’s disease (AD), are present with variable severity in bvFTD. 14,15,23 Further, given the progressive nature of dementia, clinical features tend to coalesce across disorders, presenting a challenge for…”
Self-citationFunayama, M., Kuramochi, S., & Kudo, S. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230107 · Cited by 10
“The former pattern, wherein bvFTD is misdiagnosed as other conditions, encompasses psychiatric conditions like mood disorders, anxiety disorders, or psychotic disorders [12], as well as neurological conditions including Alzheimer’s disease [14], alcohol-related dementia [15], and Lyme disease [16].”
InfluentialCustodio, N., Montesinos, R., Cruzado, L., Herrera‐Pérez, E., Failoc‐Rojas, V. E., Pintado‐Caipa, M., Wendy Seminario, G., Cuenca, J., Gamboa, C., & Diaz, M. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.704109 · Cited by 11
“Given these diagnostic challenges and the prominence of executive function and behavioral abnormalities in bvFTD, it is important to evaluate these neuropsychological markers by screening for executive dysfunction, social cognition disorders, and behavioral disturbances to distinguish bvFTD from psychiatric disorders…”
BackgroundMethodResultInfluentialHaußmann, R., Homeyer, P., Brandt, M. D., & Donix, M. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01339-6 · Cited by 11
“18Diagnostischer Algorithmus zur Liquordiagnostik bei neurodegenerativenDemenzerkrankungen Zwangsstörungen, bipolar affektiven Erkrankungen und Depressionen kann klinisch herausfordernd sein und bedarf, neben einem profunden klinischen Assessment und einer testpsychometrischen Untermauerung, ebenfalls einer umfassende…”
BackgroundInfluentialvan Engelen, M. E., Heijst, H., Willemse, E. A. J., Oudega, M. L., Vermunt, L., Scheltens, P., Vijverberg, E. G. B., Pijnenburg, Y. A. L., & Teunissen, C. E. (2023) · Brain Communications · doi:10.1093/braincomms/fcad120 · Cited by 9
“4 years till correct diagnosis.(1) Contrary to the well-validated cerebrospinal fluid (CSF) biomarkers in Alzheimer’s disease, an early specific fluid 2 | BRAIN COMMUNICATIONS 2023: Page 2 of 7 M.”
BackgroundSelf-citationHok‐A‐Hin, Y. S., Vermunt, L., Peeters, C. F. W., van der Ende, E. L., de Boer, S. C. M., Meeter, L. H. H., Houwer, J. F. H. D., Seelaar, H., Swieten, J. C. V., Hu, W. T., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00882-5 · Cited by 20
“Nevertheless, this biomarker is considered valuable for distinguishing FTD from non-neurodegenerative disorders, such as primary psychiatric diseases, and it also shows good prognostic potential [20, 21].”
Self-citationChassé, M., Pees, A., Lindberg, A., Liang, S. H., & Vasdev, N. (2023) · The Chemical Record · doi:10.1002/tcr.202300072 · Cited by 12
Moguilner, S., Báez, S., Hernandez, H., Migeot, J., Legaz, A., González-Gómez, R., Farina, F. R., Prado, P., Cuadros, J., Tagliazucchi, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03294-y · Cited by 8
Rajbanshi, B., Araujo, I. P. Q. C., VandeVrede, L. A., Ljubenkov, P. A., Staffaroni, A. M., Heuer, H. W., Lago, A. L., Ramos, E. M., Petrucelli, L., Gendron, T. F., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70078 · Cited by 15
Self-citationSerpente, M., Fenoglio, C., Arighi, A., Fumagalli, G., Arcaro, M., Sorrentino, F., Visconte, C., Scarpini, E. A., & Galimberti, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210249 · Cited by 7
“Lastly PPD were diagnosed according to Ducharme et al. (2020) [19].”
Self-citationMeysami, S., Raji, C. A., & Mendez, M. F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215667 · Cited by 9
“Given overlapping ages of onset with bvFTD and EOAD as well as the high rate of misdiagnosis in both disorders, clinically available methods for improved diagnostic accuracy are crucial [6].”
Self-citationJanicki, M. P., McCallion, P., Jokinen, N. S., Larsen, F., Mughal, D., Palanisamy, V., Santos, F. H., Service, K. P., Shih, A. J., Shooshtari, S., et al. (2025) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-025-06843-7 · Cited by 10
“Pursuit of research utilizing biomarkers could enhance diagnostic clarity (Ducharme et al., 2020; Greaves & Rohrer, 2019).”
van Engelen, M. E., Rozemüller, A. J. M., Erkoyun, H. U., Groot, C., Fieldhouse, J. L. P., Koene, T., Ossenkoppele, R., Gossink, F. T., Krudop, W. A., Vijverberg, E. G. B., et al. (2021) · Neurocase · doi:10.1080/13554794.2021.1905855 · Cited by 8
Self-citationEratne, D., Kang, M. J., Malpas, C. B., Simpson, S., Lewis, C. C., Dang, C., Grewal, J. K., Coe, A., Dobson, H., Keem, M. H., et al. (2023) · medRxiv · doi:10.1101/2023.02.19.23286151 · Cited by 8
Self-citationCalabria, F. F., Leporace, M., Cimini, A., Ricci, M., Travascio, L., & Bagnato, A. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206172 · Cited by 8
“Although no pharmacological treatment is available for FTD, a precise diagnosis is needed to rule out psychiatric disorders that are characterized by disinhibition and cognitive impairment [48].”
BackgroundKuo, C.-Y., Tseng, H.-Y., Stachiv, I., Tsai, C., Lai, Y.-C., & Nikolai, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041322 · Cited by 8
“Up-to-date data on MCI/AD and FTLD from non-Western countries—especially East Asian countries, such as China, Korea, Japan or Taiwan—are still underrepresented in the scientific literature and, correspondingly, insufficient to assess the general validity of the standard NPTs in differential diagnosis of early-stage AD…”
BackgroundMethodInfluentialde Boer, S. C. M., Riedl, L., Fenoglio, C., Rue, I., Landín-Romero, R., Matis, S., Chatterton, Z., Galimberti, D., Halliday, G. M., Diehl‐Schmid, J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230829 · Cited by 10
Self-citationBiofluid biomarkers in distinguishing young-onset dementia from primary psychiatric disorders
Loi, S. M., Eratne, D., Santillo, A. F., & Velakoulis, D. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000979 · Cited by 7
Self-citationNeurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review
Squitti, R., Fiorenza, A., Martinelli, A., Brembati, V., Crescenti, D., Rongioletti, M. C. A., & Ghidoni, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010061 · Cited by 9
Brain MRI research in neurodegenerative dementia: time to deliver on promises
Ducharme, S. (2023) · Brain · doi:10.1093/brain/awad320 · Cited by 8
Self-citationde Boer, S. C. M., Fenoglio, C., Arighi, A., Wissink, L., Riedl, L., Rue, I., Landín-Romero, R., Matis, S., Chatterton, Z., Halliday, G. M., et al. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2024-001007 · Cited by 10
Self-citationDistinct and shared neuropsychiatric phenotypes in FTLD-tauopathies
Keszycki, R. M., Kawles, A., Minogue, G., Zouridakis, A., Macomber, A. J., Gill, N. P., Vu, M. H., Zhang, H., Coventry, C., Rogalski, E. J., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1164581 · Cited by 8
“In addition to pathological heterogeneity, the presence of neuropsychiatric symptoms in this younger patient population, particularly early in the disease course, may obfuscate differential diagnosis from primary psychiatric disorders (Ducharme et al., 2020).”
BackgroundBurhan, A. M., Anazodo, U., Marlatt, N. M., Palaniyappan, L. K., Blair, M., & Finger, E. C. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03341-9 · Cited by 8
“morphology in some patients with bvFTD with C9orf72 [12] (see Fig.”
BackgroundInfluentialPrimary Progressive Aphasia Presenting With Neuropsychiatric Symptoms
Mulder-Heijstra, M., Jokel, R., Chertkow, H. M., Conn, D. K., & Mah, L. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211036189 · Cited by 7
Fieldhouse, J. L. P., van Engelen, M. E., Handgraaf, D., de Boer, S. C. M., Hooft, J. J. V. ’., Schouws, S. N. T. M., van Grootheest, D., Kerssens, C. J., Duits, F. H., van Harten, A. C., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16426 · Cited by 6
“Several core features of bvFTD, which include the symptoms of apathy, disinhibition, and stereotypy, show considerable overlap with symptoms of major depressive disorder (MDD), bipolar disorder, schizophrenia, and obsessive– compulsive disorder (OCD) [ 2, 3 ].”
BackgroundSelf-citationMorrow, C. B., Chaney, G.-A. S., Capuzzi, D., Bakker, A., Onyike, C. U., & Kamath, V. J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220443 · Cited by 7
“…that the utility of designating a ‘questionable’ hyperorality category may be limited, and that more thorough clinical characterization of hyperorality with tools like the Appetite and Eating Habits Questionnaire (APEHQ), the DAPHNE scale or Cambridge Behavioral Inventory are preferred [4, 38, 39].”
Self-citationvan Paassen, D. N., Hartog, W. L., de Boer, S., Vijverberg, E. G. B., Ducharme, S., Pijnenburg, Y. A. L., & Santillo, A. F. (2024) · European Journal of Neurology · doi:10.1111/ene.16537 · Cited by 7
Self-citationTuovinen, T., Häkli, J., Rytty, R., Krüger, J., Korhonen, V. O., Järvelä, M., Helakari, H., Kananen, J., Nikkinen, J., Veijola, J., et al. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241262583 · Cited by 5
“14,17,18 Differentiating among the various neurodegenerative causes of dementia enables affected individuals and their families to receive suitable treatment, support, and care.”
Self-citationA Systematic Review of the Genetics and Pathology of Psychosis in Frontotemporal Dementia
Chatterjee, A., Hirsch‐Reinshagen, V., Scott, I. M., Cashman, N. R., & Hsiung, G. R. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.248 · Cited by 7
“4,8 Hence, we believe that the true prevalence of psychotic symptoms in FTD remains uncertain.”
Behavioral Variant of Frontotemporal Dementia and Homicide in a Historical Case.
Zago, S., Scarpazza, C., Difonzo, T., Arighi, A., Hajhajate, D., Torrente, Y., & Sartori, G. (2021) · PubMed · doi:10.29158/jaapl.200081-20 · Cited by 6
Rizzi, L., Aventurato, Í. K., & Balthazar, M. L. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.640525 · Cited by 8
Current clinical and research practices on frontotemporal dementia in Brazil: a national survey
de Souza, L. C., Brucki, S. M. D., Schilling, L. P., da Silva, L. C., Takada, L. T., Bahia, V. S., Barbosa, B. J. A. P., Balthazar, M. L. F., Frota, N. A. F., Nitríni, R., et al. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1771173 · Cited by 8
Self-citationCerebrospinal-fluid Orexin-A levels in different neurocognitive disorders: a comparison study
Lozano-Tovar, S., Cremascoli, R., Nuccetelli, M., Sancesario, G., Cattaldo, S., Prina, E., Verde, F., Cappelli, S., Bernardini, S., Mercuri, N. B., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08148-0 · Cited by 8
“Moreover, a group of patients diagnosed as affected by the NFPA was also included in the study [24]. iNPH was diagnosed according to the iNPH guideline criteria, based on the results of clinical and brain magnetic resonance imaging (MRI), and confirmed by a positive spinal tap test [25–26].”
Tau and tauopathies across primate species: implications for modeling neurodegenerative disorders
Colwell, J. C., & Emborg, M. E. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1598245 · Cited by 11
“Misdiagnoses, especially between FTD and primary psychiatric disorders, are not uncommon (Ducharme et al., 2020).”
Funayama, M., Nakajima, A., Kurose, S., & Takata, T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210501 · Cited by 5
Saracino, D., & Ber, I. L. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.007 · Cited by 7
Fittipaldi, S., Legaz, A., Maito, M. A., Hernandez, H., Altschuler, F., Canziani, V., Moguilner, S., Gillan, C. M., Castillo, J., Lillo, P., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3007086/v1 · Cited by 7
Self-citationVanderlinden, G., Carron, C. P., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01224-5 · Cited by 7
“18 F-FDG is also not specific in the differential diagnosis between psychiatric disorders and neurodegeneration such as for behavioral variants of FTD [8].”
BackgroundSelf-citationde Souza, L. C., Hosogi, M. L., Machado, T. H., Carthery‐Goulart, M. T., Yassuda, M. S., Smid, J., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., Frota, N. A. F., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s103en · Cited by 12
Self-citationInitial symptoms of early‐onset dementia in Japan: nationwide survey
Edahiro, A., Okamura, T., Arai, T., Ikeuchi, T., Ikeda, M., Utsumi, K., Ota, H., Kakuma, T., Kawakatsu, S., Konagaya, Y., et al. (2023) · Psychogeriatrics · doi:10.1111/psyg.12949 · Cited by 7
Self-citationSchröder, S., Bönig, L., Proskynitopoulos, P. J., Janke, E., Heck, J., Mahmoudi, N., Groh, A., Berding, G., Wedegärtner, F., Deest‐Gaubatz, S., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04759-z · Cited by 6
“Due to its clinical heterogeneity, bv-FTD can mimic a depressive episode, especially its initial stages [7].”
BackgroundBruinsma, J., Peetoom, K. K. B., Verhey, F. R. J., Bakker, C., & de Vugt, M. E. (2022) · Dementia · doi:10.1177/14713012221126312 · Cited by 14
“Typically, the early symptoms start insidious and are often misattributed for work-related stress, psychiatric symptoms, marital issues, or as the result of a midlife crisis (Ducharme et al., 2020; Bruinsma, Peetoom, Bakker et al., 2020).”
BackgroundFieldhouse, J. L. P., Singleton, E. H., van Engelen, M. E., Hooft, J. J. V. ’., de Boer, S. C. M., Froeling, V. E., Braun, M., Oudega, M. L., van Grootheest, D., Kerssens, C. J., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15837 · Cited by 7
“Recent consensus recommendations of the Neuropsychiatric International Consortium for Frontotemporal Dementia stressed that crossdisorder phenotyping of social cognition is needed [6, 9].”
BackgroundSelf-citationKatisko, K., Krüger, J., Soppela, H., Hartikainen, P. H., Haapasalo, A., Remes, A. M., & Solje, E. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230494 · Cited by 6
Coulborn, S., Roy, A. R. K., Sokołowski, A., Cryns, N. G., Lago, A. L., Cobigo, Y., Rojas, J. C., Spina, S., Grinberg, L. T., Rankin, K. P., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70771 · Cited by 6
“10 14 Studies using cerebrospinal fluid (CSF) NfL have demonstrated strong discriminatory power between bvFTD and PPDs. 15,16 20 Glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, has also been investigated; however, it was previously found to be inferior to NfL, with no…”
Self-citationMusic appreciation phenotypes in patients with frontotemporal dementia: A pilot study
Hooft, J. J. V. ’., Fieldhouse, J. L. P., Singleton, E. H., Jaschke, A. C., Warren, J. D., Tijms, B. M., & Pijnenburg, Y. A. L. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5793 · Cited by 9
Self-citationSemenkova, A., Piguet, O., Johnen, A., Schroeter, M. L., Godulla, J., Linnemann, C., Mühlhauser, M., Sauer, T., Baumgartner, M., Anderl‐Straub, S., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11666-6 · Cited by 6
“Indeed, up to 50% of bvFTD patients are first diagnosed with PPD and vice versa [15, 29], of which major depressive disorder * Marc Sollberger marc.sollberger@felixplatter.ch Extended author information available on the last page of the article 1 3 (MDD) is probably the most common misdiagnosis [21, 29, 36].”
BackgroundSelf-citationGambogi, L. B., de Souza, L. C., & Caramelli, P. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s140 · Cited by 7
Self-citationBarbosa, I. G., Leite, F. D. M. C., Bertoux, M., Guimarães, H. C., Mariano, L. I., Gambogi, L. B., Teixeira, A. L., Caramelli, P., & de Souza, L. C. (2023) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2935 · Cited by 12
Self-citationDifferentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders
de Boer, S. C. M., Riedl, L., Braak, S., Fenoglio, C., Foxe, D., Carrick, J., Landín-Romero, R., Matis, S., Chatterton, Z., Rue, I., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf199 · Cited by 5
“9,56 While shedding important light on the differential diagnosis between sporadic bvFTD and PPD, findings from this study need to be interpreted with caution.”
Self-citationde Souza, L. C., Hosogi, M. L., Machado, T. H., Carthery‐Goulart, M. T., Yassuda, M. S., Smid, J., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., Frota, N. A. F., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s103pt · Cited by 27
Self-citationSelf-Mastery and Dementia Caregiver Burden: A Systematic Review and Meta-Analysis
Cousins, E., Burke, E. M., & Spitznagel, M. B. (2025) · Clinical Gerontologist · doi:10.1080/07317115.2025.2477588 · Cited by 7
Li, H., Xiong, L., Xie, T., Wang, Z., Li, T., Zhang, H., Wang, L., Yu, X., & Wang, H. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac487 · Cited by 5
Alsubai, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-09862-7 · Cited by 7
“Although various studies have investigated strategies for diagnosing illnesses such as ASD, dementia, and learning difficulties, many of them rely largely on lengthy interviews and extensive questionnaires 20 .”
Sejourne, C., Dworkin, J. D., Barker, M. S., Manoochehri, M., Gottesman, R. T., Wassermann, E. M., Tierney, M. C., Huey, E. D., & Grafman, J. H. (2022) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221130267 · Cited by 6
“1% in Alzheimer’s disease dementia (AD).(3,7) Major Depressive Disorder (MDD) is an especially common early diagnosis in patients with”
BackgroundSelf-citationVery early onset dementias: Importance of differentiating from schizophrenia spectrum disorders
McCormick, L. H., Bodla, A. P., & Rubín, R. T. (2024) · PLOS mental health. · doi:10.1371/journal.pmen.0000107 · Cited by 5
Quantifying multimodal longitudinal brain changes in presymptomatic C9orf72 disease
Saracino, D., Cipriano, L., Houot, M., Querin, G., Rinaldi, D., Rametti‐Lacroux, A., Wallon, D., Gérardin, E., Couratier, P., Boncoeur, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70902 · Cited by 4
“57,58 Moreover, a unique clinico-pathological report identified DPR inclusions and RNA foci in association with focal pulvinar atrophy but without frank TDP-43 pathology or brain-wide degeneration.”
Tafuri, B., Filardi, M., Frisullo, M. E., Blasi, R. D., Rizzo, G., Nigro, S. L., & Logroscino, G. (2023) · Brain and Behavior · doi:10.1002/brb3.2896 · Cited by 4
Applications of MRI in Schizophrenia: Current Progress in Establishing Clinical Utility
Sun, H. J., Liu, N., Qiu, C., Tao, B., Yang, C., Tang, B., Li, H., Zhan, K., Cai, C., Zhang, W., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29470 · Cited by 6
“92 A recent meta-analysis suggested that 26.4% of FEP patients had an intracranial radiological abnormality, and 5.9% had a clinically relevant abnormality, yielding that 18 of patients needed to scan to detect 1 such abnormality, enhancing the necessity of using MRI as routine clinical assessment…”
InfluentialFernqvist, A., Alexiou, E., Zetterberg, H., Howner, K., Nilsson, T., & Andiné, P. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1176266 · Cited by 5
“There is growing evidence that primary psychiatric disorders, in general, and psychotic disorders, in particular, are not characterized by increased levels of NfL in the cerebrospinal fluid (18, 20) or blood (16–18), not even in patients with treatment-resistant schizophrenia (21), a group with profound cognitive defi…”
BackgroundThe role of brain perfusion SPECT in the diagnosis of frontotemporal dementia: A systematic review
Athanasio, B. D. S., Oliveira, A. C. D. S., Pedrosa, A. L., Borges, R. D. S., Neto, A. O. M., Oliveira, R. A., Resende, E. D. P. F., de Moraes, R. F., Caramelli, P., & de Souza, L. C. (2024) · Journal of Neuroimaging · doi:10.1111/jon.13189 · Cited by 4
Self-citationDirect detection of C9orf72 hexanucleotide repeat expansions by nanopore biosensor
Li, X., Rao, G., Peng, X., Yang, C., Zhang, Y., Tian, Y., Fu, X., & Geng, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109419 · Cited by 4
The conundrum of the connection between severe psychiatric disorders and dementia
Teixeira, A. L., de Erausquin, G. A., & Olvera, R. L. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0223 · Cited by 7
“Regardless of these controversies, the symptomatic resemblance between features of mania/hypomania episodes and FTD is unequivocal, sometimes leading to a diagnostic challenge 41,42 .”
Receptor-Independent Therapies for Forensic Detainees with Schizophrenia–Dementia Comorbidity
Sfera, A., Andronescu, L., Britt, W. G., Himsl, K., Klein, C. A., Rahman, L., & Kozlakidis, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115797 · Cited by 3
“This complicates not only the differential diagnosis but also the psychopharmacological management of SCZ with overlapping dementia.”
BackgroundPotential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview
Manzine, P. R., Vatanabe, I. P., Grigoli, M. M., Pedroso, R. V., Monteiro, M. P. A. O., de Oliveira, D. D. S. M. S., Nascimento, C. M. C., Peron, R., Orlandi, F. D. S., & Cominetti, M. R. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220408124809 · Cited by 5
Shafiei, G., Bazinet, V., Dadar, M., Manera, A. L., Collins, D. L., Dagher, A., Borroni, B., Sánchez‐Valle, R., Moreno, F., Laforce, R. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.24.457538 · Cited by 4
“Clinically this is reflected by progressive cortical atrophy, which is a crucial biomarker for the diagnosis [21, 36].”
BackgroundSelf-citationGiudici, G., Fenoglio, C., Serpente, M., Arighi, A., Arcaro, M., Delvecchio, G., Brambilla, P., Sacchi, L., Pintus, M., Borracci, V., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107132 · Cited by 4
Self-citationHok‐A‐Hin, Y. S., Vermunt, L., Peeters, C. F. W., van der Ende, E. L., de Boer, S. C. M., Meeter, L. H. H., Swieten, J. C. V., Hu, W. T., Lleó, A., Alcolea, D. A., et al. (2024) · medRxiv · doi:10.1101/2024.08.19.24312100 · Cited by 4
Self-citationChallenging Assumptions Around Dementia: User-led Research and Untold Stories
Ashworth, R., Fyvel, S., Hill, A., Maddocks, C., Qureshi, M., Ross, D., Hay, S., Robertson, M., Gilder, W., Henry, W., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-27223-3 · Cited by 7
C9orf72 Repeat Expansion Initially Presenting as Late-Onset Bipolar Disorder With Psychosis
Gaynor, L. S., Yadollahikhales, G., Tsoy, E., Hall, M., Boxer, A. L., Miller, B. L., & Grinberg, L. T. (2023) · The Neurologist · doi:10.1097/nrl.0000000000000527 · Cited by 4
The search for a link between autism spectrum disorder and neurodegenerative dementia
Fumagalli, G., & Crippa, A. (2022) · Minerva Psychiatry · doi:10.23736/s2724-6612.22.02370-3 · Cited by 2
He, C., Wang, Y., Bai, H., Li, R., & Fang, X. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3741677 · Cited by 3
“Its clinical manifestations include lack of interest, persistent depressive mood, and anhedonia [1].”
BackgroundAlastalo, A., Tolppanen, A., Nietola, M., Haapea, M., Miettunen, J., Hartikainen, S. A., & Jääskeläinen, E. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13423 · Cited by 2
Dodich, A., Panzavolta, A., Funghi, G., Meli, C., Festari, C., Chatzikostopoulos, A., Chicherio, C., Clarens, M. F., de Oliveira, F. F., Filardi, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01908-2 · Cited by 7
“…phenotype, also in light of the new evidence in favor of including socio-cognitive deficits as neuropsychological criterium for the diagnosis of the behavioral variant of frontotemporal dementia (bvFTD) [6], yet in prodromal phase [7], as well to better reach a correct differential diagnosis [8].”
Self-citationFesharaki‐Zadeh, A., Çayır, S., Ibrahim, W., Yang, Y., Gallezot, J., Naganawa, M., Wu, Y., Toyonaga, T., Sadabad, F. E., O’Dell, R. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71283 · Cited by 4
Goodwin, G. J., Cacho, J. R. F., Mehrzad, S., Cummings, J. L., & John, S. E. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70782 · Cited by 3
“73,74 Finally, our sample was predominantlynon-Hispanicwhiteandnotrepresentativeofthelarger patientpopulation.”
Ilchovska, Z. G., Lockwood, J., Proctor, E., Hosseini, A. A., Ralph, M. A. L., & Jung, J. (2025) · medRxiv · doi:10.1101/2025.06.02.25328809 · Cited by 3
Liu, E., Jones, S. L., Light, V., Teunissen, C. E., Bouzigues, A., Russell, L. L., Foster, P. H., Ferry‐Bolder, E., Swieten, J. C. V., Jiskoot, L. C., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352103 · Cited by 4
“11 Therefore, blood-based (serum and plasma) NfL is emerging as a candidate biomarker to differentiate bvFTD (high levels) from PPD (normal to mildly elevated levels).”
Self-citationBaudouin, É., Duron, E., Verdoux, M., Gasnier, M., Pelloux, Y., Bottemanne, H., Corruble, E., & Colle, R. (2025) · BMJ Mental Health · doi:10.1136/bmjment-2025-301651 · Cited by 4
Konstantinopoulou, E., Vilou, I., Falega, I., Papadopoulou, V., Chatzidimitriou, E., Grigoriadis, N., Aretouli, E., & Ioannidis, P. (2023) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acad101 · Cited by 3
“Although eachofthesetestshasdifferentsensitivityandspecificityfor thedifferentialdiagnosisofdementia,theyallhavelowsensitiv-ityforthedetectionofbvFTD,unlikescreeningtoolsthatare moresensitivetodetectdeficitsinEF(Ducharmeetal.,2020).”
Mondésert, E., Cristol, J., Bargnoux, A., Duchiron, M., Busto, G. U., Hirtz, C., Barnier-Figue, G., Perrein, F., Turpinat, C., Jurici, S., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214931 · Cited by 6
Flavell, J., Ahern, E. G. M., Logan, B., Shaw, T. B., Adam, R. J., McElligott, C. A. T., & Nestor, P. J. (2025) · European Journal of Neurology · doi:10.1111/ene.70036 · Cited by 7
Loi, S. M., Eratne, D., Cadwallader, C. J., Ravanfar, P., Chadunow, C., Vidaurre, L., Farrand, S., Kelso, W. M., Goh, A., Watson, R., et al. (2021) · medRxiv · doi:10.1101/2021.07.03.21259825 · Cited by 4
“There is a clear need for high quality research studies to develop accurate, accessible and equitable diagnostic tools to diagnose YOD (Ducharme et al., 2020).”
BackgroundSelf-citationPeltier, C., Lejeune, F., Jorgensen, L. G. T., Rametti‐Lacroux, A., Tanguy, D., Godefroy, V., Bendetowicz, D., Carle, G., Cognat, E., Bombois, S., et al. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109625 · Cited by 4
Chronic apathy following a major depressive episode: What is it?
Morin, A., Bernard, J., Carle, G., Ponchel, A., Azuar, C., Uggocioni, G., Mauras, T., Bendetowicz, D., Camus, M., Delcul, A., et al. (2025) · Cortex · doi:10.1016/j.cortex.2025.04.008 · Cited by 3
Self-citationRue, I., Jones, S. L., de Boer, S. C. M., Soltaninejad, M., Diehl‐Schmid, J., Galimberti, D., Arighi, A., Halliday, G. M., Landín-Romero, R., Piguet, O., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13467-5 · Cited by 2
“Ambiguous scans were coded as negative for the accuracy calculations in accordance with the current recommendations to distinguish bvFTD from psychiatric disorders [2].”
InfluentialSelf-citationThe impact of sex on clinical profiles of patients with behavioral variant frontotemporal dementia
Afrooz, P., St-Georges, M.-A., Carrier, T., Zeighami, Y., Dadar, M., & Montembeault, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70996 · Cited by 2
“4 Diagnosis of bvFTD still remains a challenging task due to a lack of awareness in general practitioners combined with the overlap of the symptoms with psychiatric disorders 5 or other neurodegenerative diseases such as Alzheimer’s dementia or primary progressive aphasia 6,7 .”
Behavioural variant frontotemporal dementia – selected diagnostic dilemmas in neuropsychiatry
Oddział Psychogeriatryczny, S. D. N. I. P. C. W. S. G., Kuklińska, M., Sitek, E. J., Oddział Neurologii, S. S. Ś. W., Brockhuis, B., Barczak, A. K., Zakład Badawczo-Leczniczy Chorób Zwyrodnieniowych CUN, I. M. D. I. K. I. M. M., Oddział Alzheimerowski, K. N., Hintze, B., Zakład Psychologii Klinicznej Człowieka Dorosłego, A. P. S. I. M. G., et al. (2020) · Aktualności Neurologiczne · doi:10.15557/an.2020.0010 · Cited by 1
Everyday functioning in young onset dementia: differences between diagnostic groups
Weltings, E., Postema, M. C., van Dam, M., Dubbelman, M. A., Tewolde, M. E., Duits, F. H., Lemstra, A. W., Dickerson, B. C., Carrillo, M. C., Rabinovici, G. D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70711 · Cited by 2
“10,11 An essential part of the diagnostic process is the extent to which cognitive impairments impact everyday functioning, 12 which can be objectified using the construct of Instrumental Activities of Daily Living (IADL).”
Self-citationMotor Neuron Disease & Frontotemporal Dementia Presenting with a Conversion Disorder
Wibawa, P., O’Connor, R., Kenchaiah, B. K., & Velakoulis, D. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100082 · Cited by 2
Self-citationGuarnier, G., Reinelt, J. D., Molloy, E. N., Mihai, P. G., Einaliyan, P., Valk, S. L., Modestino, A. E., Ugolini, M., Mueller, K., Wu, Q., et al. (2024) · medRxiv · doi:10.1101/2024.09.23.24314186 · Cited by 4
“One explanation for this relates to the variety of behavioral and psychological symptoms that occur in dementia (BPSD) 59,60 and how these characterize different dementia disorders 61 .”
BackgroundObsessive-compulsive symptoms in dementia: Systematic review with meta-analysis
Martinho, F. P., Ferreira, T. F., Magalhães, D., Felício, R., & Godinho, F. (2024) · L Encéphale · doi:10.1016/j.encep.2024.06.001 · Cited by 2
Brain clocks capture diversity and disparity in aging and dementia
(2024) · doi:10.21203/rs.3.rs-4150225/v1 · Cited by 2
Chatterton, Z., de Boer, S. C. M., Riedl, L., Matis, S., Fenoglio, C., Rue, I., Landín-Romero, R., Southwood, D., Galimberti, D., Arighi, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22667-y · Cited by 3
Self-citation
Metadata
- Authors
- Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., Huey, E., Vandenbulcke, M., Masellis, M., Trieu, C., Onyike, C., Caramelli, P., de Souza, L. C., Santillo, A., Waldö, M. L., Landin-Romero, R., Piguet, O., Kelso, W., Eratne, D., Velakoulis, D., Ikeda, M., Perry, D., Pressman, P., Boeve, B., Vandenberghe, R., Mendez, M., Azuar, C., Levy, R., Le Ber, I., Baez, S., Lerner, A., Ellajosyula, R., Pasquier, F., Galimberti, D., Scarpini, E., van Swieten, J., Hornberger, M., Rosen, H., Hodges, J., Diehl-Schmid, J., & Pijnenburg, Y.
- Affiliations
- Montreal Neurological Institute and Hospital (CA)
- Amsterdam Neuroscience (NL)
- Université Laval (CA)
- The University of Sydney (AU)
- Laboratory for Translational Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium
- CERVO brain Research Centre, Laval University, Quebec, Canada
- Erasmus MC (NL)
- Columbia University (US)
- Universitair Ziekenhuis Leuven (BE)
- Sunnybrook Health Science Centre (CA)
- Johns Hopkins University (US)
- Universidade Federal de Minas Gerais (BR)
- Behavioral and Cognitive Neurology Research Group, Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Lund University (SE)
- Brain and Mind Centre, University of Sydney, Sydney, Australia
- The Royal Melbourne Hospital (AU)
- The University of Osaka (JP)
- University of California, San Francisco (US)
- University of Colorado Denver (US)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Pitié-Salpêtrière Hospital (FR)
- Department of Neurology, Hôpital La Pitié Salpêtrière, Paris, France
- Department of Psychology, Andes University, Bogota, Colombia
- University Hospitals of Cleveland (US)
- Manipal Hospital (IN)
- Inserm (FR)
- University of Milan (IT)
- Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
- Department of Medicine, Norwich Medical School, Norwich, UK
- Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany
- Corresponding author
- Ducharme, Simon
- ORCID
- Ducharme, Simon
- Dols, Annemiek
- Laforce, Robert
- Devenney, Emma
- Kumfor, Fiona
- van den Stock, Jan
- Seelaar, Harro
- Gossink, Flora
- Vijverberg, Everard
- Huey, Edward
- Vandenbulcke, Mathieu
- Masellis, Mario
- Trieu, Calvin
- Onyike, Chiadi
- Caramelli, Paulo
- Santillo, Alexander
- Waldö, Maria Landqvist
- Landin-Romero, Ramon
- Piguet, Olivier
- Kelso, Wendy
- Eratne, Dhamidhu
- Velakoulis, Dennis
- Ikeda, Manabu
- Perry, David
- Pressman, Peter
- Boeve, Bradley
- Vandenberghe, Rik
- Mendez, Mario
- Lerner, Alan
- Ellajosyula, Ratnavalli
- Pasquier, Florence
- Galimberti, Daniela
- Scarpini, Elio
- Hornberger, Michael
- Rosen, Howard
- Hodges, John
- Pijnenburg, Yolande
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-04
- Volume
- 143
- Issue
- 6
- Pages
- 1632-1650
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC7849953
- OpenAlex
- W3009452141
- Cited by
- 320
- References
- 202
- Citations by year
- 2026: 39 · 2025: 53 · 2024: 64 · 2023: 56 · 2022: 57 · 2021: 43 · 2020: 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Lirias (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Fond de Recherche du Québec–Santé
- NIH
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- behavioral variant frontotemporal dementia, differential diagnosis, mental illness, delayed diagnosis, clinical evaluation, FDG-PET, neurofilament light chain, neuropsychological assessment
- MeSH terms
- Mental Disorders, Diagnosis, Differential, Female, Humans, Magnetic Resonance Imaging, Male, Neurologic Examination, Neuropsychological Tests, Fluorodeoxyglucose F18, Positron-Emission Tomography, Frontotemporal Dementia, Delayed Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.